stella
beta
Tislelizumab Combined With Thoracic Radiotherapy as Neoadjuvant Therapy for Resectable NSCLC — Stella
Recruiting
Back to Resectable NSCLC trials
Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.
Trial locations
(1 site)
China
Jiangsu Northern People Hospital, Yangzhou, Jiangsu
View full record on ClinicalTrials.gov